The Center for Lung Disease and Transplantation at NewYork-Presbyterian Hospital provides comprehensive, coordinated, multidisciplinary care to adults and children with every type of lung disease. Patients are evaluated and treated at the Columbia University Medical Center (uptown) campus of NewYork-Presbyterian Hospital.
Specialized programs within or affiliated with the Center for Lung Disease and Transplantation include:
Doctors in these programs effectively treat patients with some conditions using less invasive alternatives that may enable patients to avoid transplantation or may serve as a bridge to lung transplantation and delay this difficult treatment option.
Lung transplantation can prolong the lives of patients with severe pulmonary disease and no alternative treatment options, and dramatically improves their quality of life.
Transplantation is usually offered to patients who have end-stage lung failure and an expected survival of one to two years. End-stage lung failure can develop from the following diseases:
NewYork-Presbyterian is a leader in advancing techniques and patient selection criteria for lung transplantation in adults and children with cystic fibrosis (CF). As a result, the Hospital has the largest CF lung transplant program in the New York metropolitan area.
Although current management strategies reasonably control the disease for most children with CF into adulthood, lung transplantation offers extended survival in patients with advancing disease who have severe and irreversible airflow obstruction. Transplanted patients with CF may now undergo subsequent transplantation if their initial transplant fails.
Surgeons from the Heart Failure and Transplantation Program and the Center for Lung Disease and Transplantation at NewYork-Presbyterian collaborate to perform combination heart and lung transplants for patients who need both organs transplanted.
Center for Lung Disease and Transplantation